Sama Therapeutics

Executive Summary

Sama Therapeutics is a Cambridge, MA-based biotechnology company that combines artificial intelligence and computational neuroscience to advance precision neuropsychiatry. Its core asset is the iMAGiNE™ platform, a software-as-a-medical-device (SaMD) solution that uses predictive biomarkers to personalize brain health assessments and accelerate therapeutic development. The company focuses on cognitive, affective, interoceptive, and substance use disorders, positioning itself at the intersection of AI-driven diagnostics and neuropsychiatric drug development. As a pre-clinical stage private company, Sama has not disclosed funding or valuation details but represents an emerging player in the digital biomarker space, targeting a market with high unmet need and growing interest in precision medicine for mental health. Sama's strategy leverages its proprietary AI platform to identify patient subtypes and predict treatment responses, potentially enabling faster, more efficient clinical trials. While still in early stages, the company's approach aligns with industry trends toward decentralized trials and biomarker-based patient stratification. Key upcoming milestones include potential partnerships with pharmaceutical companies for platform validation, which could provide proof-of-concept data and revenue opportunities. The company's success hinges on securing further financing and demonstrating the platform's ability to improve outcomes in neuropsychiatric indications. With a focused vision and strong scientific foundation, Sama Therapeutics is well-positioned to contribute to the next generation of brain health solutions.

Upcoming Catalysts (preview)

• Q3 2026Pharma Partnership for iMAGiNE Platform Validation40% success
• Q4 2026Series A Funding Announcement50% success
• Q1 2027First IND Filing for Digital Biomarker Trial30% success